Locksley Resources (ASX: LKY) hits 99.5% purity antimony trioxide milestone, opening U.S. defense supply chain pathway
How Accenture is using Google Cloud and Wiz to close security blind spots in modern multi-cloud infrastructure
Read More 6 minute read Pharma Industry News Q32 Bio divests complement inhibitor ADX-097 as Akebia Therapeutics builds rare kidney disease pipeline Discover how Q32 Bio’s ADX-097 sale to Akebia Therapeutics reshapes both companies’ pipelines, balance sheets, and investor outlook. bySoujanya RaviDecember 1, 2025